Acadia Pharma (ACAD) Misses Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $19.73 -2.86%
Revenue Growth %: +19.3%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +19.3%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.40), $0.13 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $4 thousand versus the consensus estimate of $80 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
